SynBioBeta Speaker

Andrei Georgescu

Vivodyne

CEO

Andrei Georgescu, PhD, leads Vivodyne, where lab-grown human tissues are robotically tested at industrial, AI-enabling scale to create human data before clinical trials. The company operates 30,000 square feet of automated biological datacenters across San Francisco and Philadelphia, partnering with the majority of the top-10 pharmaceutical companies to discover and develop better, safer medicines that succeed in clinical trials. He holds a Ph.D. in Bioengineering from the University of Pennsylvania.

Sessions Featuring

Andrei

This Year

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Previous Speakers Include